AmSurg Shares Rise in Value After $2.35B Sheridan Deal Announcement

Raymond James analyst John Ransom set AmSurg’s price target at $60 and upgraded his recommendation to “buy,” according to a Value Walk report.

Advertisement
Carrie Pallardy

The upgrade was made closely following AmSurg’s announcement of intention to acquire Sheridan Healthcare for $2.35 billion.

More Articles on Transactions and Valuation Issues:
4 Recent ASC Industry Acquisitions
Beloit Health System ASC Project Remains in Limbo
3 Recently Opened & Expanded Ambulatory Surgery Centers

From data overload to intelligent decisions: How AI agents will reshape health system efficiency by 2030

Recommended OnDemand Webinar

Advertisement

Next Up in ASC Transactions & Valuation Issues

Advertisement

Comments are closed.